Patent: 10,420,754
✉ Email this page to a colleague
Summary for Patent: 10,420,754
| Title: | Use of maleimide derivatives for preventing and treating cancer |
| Abstract: | The present invention is related to a compound of formula (I): ##STR00001## a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N--R.sup.1, O and S; R.sup.1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R.sup.2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R.sup.3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl. |
| Inventor(s): | Beller; Matthias (Nienhagen, DE), Lukas; Jan (Rostock, DE), Frech; Moritz (Neu Broderstorf, DE), Junghanss; Christian (Rostock, DE), Pews-Davtyan; Anahit (Rostock, DE) |
| Assignee: | Centogene AG (Rostock, DE) |
| Application Number: | 16/004,994 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,420,754
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2032-12-10 |
| Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2032-12-10 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2032-12-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
